# EDGAR Filing Document

**Accession Number:** 0001847345
**File Stem:** 0001493152-25-022580
**Filing Date:** 2025-11
**Character Count:** 138859
**Document Hash:** 15fef56ee4e09231e3f665af3403344f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-022580.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001493152-25-022580

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251111

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aspire Biopharma Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001847345
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41293
- **FILM NUMBER:** 251481324

**BUSINESS ADDRESS:**
- **STREET 1:** 23150 FASHION DRIVE, SUITE 232
- **CITY:** ESTERO
- **STATE:** FL
- **ZIP:** 33928
- **BUSINESS PHONE:** 561-704-8527

**MAIL ADDRESS:**
- **STREET 1:** 23150 FASHION DRIVE, SUITE 232
- **CITY:** ESTERO
- **STATE:** FL
- **ZIP:** 33928

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PowerUp Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PowsedrUp Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210222

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 11, 2025**

**Aspire Biopharma Holdings, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41293** | **33-3467744** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File No.) | (I.R.S. Employer<br> Identification No.) |

---

**23150 Fashion Drive, Suite 230**

**Estero, Florida 33928**

(Address of Principal Executive Offices)

**(415) 592-7399**

(Registrant's Telephone Number)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common stock, par value $0.0001 per share** | **ASBP** | **The Nasdaq Stock Market LLC** |
| **Warrants, each exercisable for one share of common stock** | **ASBPW** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

***Equity Line of Credit***

On November 11, 2025, the Company entered into a Purchase Agreement ("ELOC Agreement") with Arena Business Solutions Global SPC II, Ltd. ("Arena"). Under the ELOC Agreement, the Company has the right, but not the obligation, to direct Arena to purchase up to $100,000,000 in shares of the Company's common stock (the "ELOC Shares") upon satisfaction of certain terms and conditions contained in the ELOC Agreement, including, without limitation, an effective registration statement filed with the SEC registering the resale of ELOC Commitment Shares (as defined below) and additional shares to be sold to Arena from time to time under the ELOC Agreement. The term of the ELOC Agreement began on the date of execution and ends on the earlier of (i) the first day of the month next following the 36-month anniversary of the execution date, (ii) the date on which the Investor shall have purchased the maximum amount of ELOC Shares, or (iii) the effective date of any written notice of termination delivered pursuant to the terms of the ELOC Agreement (the "Commitment Period").

During the Commitment Period, the Company may direct Arena to purchase ELOC Shares by delivering a notice (an "Advance Notice") to Arena. The Company shall, in its sole discretion, select the amount of ELOC Shares requested by the Company in each Advance Notice. However, such amount may not exceed the Maximum Advance Amount (as defined in the ELOC Agreement). The purchase price to be paid by Arena for the ELOC Shares will be ninety-six percent (96%) of the VWAP (as defined in the ELOC Agreement) of the Company's common stock during the trading day commencing on the date of the Advance Notice, subject to adjustment pursuant to the terms of the ELOC Agreement.

In consideration for Arena's execution and delivery of the ELOC Agreement, the Company agreed to issue or cause to be issued or transferred to Arena [ ] shares of common stock (the "Transaction Fee Shares"). In addition, the Company has agreed all of Arena's customary due diligence and legal fees, in an amount of up to approximately $20,000 plus an amount of $25,000 incurred in a prior transaction between the Company and Arena, for a total of $40,000, $20,000 of which was to be paid upon execution and delivery of the ELOC Agreement and the remainder of the balance will be paid by the issuance to Arena of 162,338 shares of our common stock.

Under the ELOC Agreement, the Company also agreed to, no later than ten (10) business days following the Closing of the Business Combination, file with the SEC a registration statement for the resale by Arena of the ELOC Shares and the ELOC Commitment Shares, and to file one or more additional registration statements if necessary.

The ELOC Agreement contains customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. Among other things, Arena represented to the Company, that it is an "accredited investor" (as such term is defined in Rule 501(a) of Regulation D under the Securities Act). The Company issued, and will issue, the securities in reliance upon an exemption from registration contained in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

The foregoing description of the ELOC Agreement and Leak Out Agreement, are qualified in its entirety by reference to the full text of such agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

**Item 1.02. Termination of a Material Definitive Agreement.**

***Termination of Original Equity Line of Credit***

As previously reported, on February 13, 2025, the Company entered into a Purchase Agreement ("Original ELOC Agreement") with Arena whereby the Company had the right, but not the obligation, to direct Arena to purchase up to $100,000,000 in shares of the Company's common stock upon satisfaction of certain terms and conditions contained in the Original ELOC Agreement. For a full description of the Original ELOC Agreement, please refer to the Company's Current Report on Form 8-K and the exhibits attached thereto as filed on February 20, 2025.

On November 11, 2025, the Company and Arena entered into a Termination Agreement (the "Termination Agreement") pursuant to which the Company and Arena mutually terminated the Original ELOC Agreement, pursuant to Section 11.02 thereof, effective immediately.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.**

The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

**Item 3.02. Unregistered Sales of Equity Securities.**

The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Form of Purchase Agreement](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASPIRE BIOPHARMA HOLDINGS, INC.** | **ASPIRE BIOPHARMA HOLDINGS, INC.** |
|  | By: | */s/ Kraig Higginson* |
|  |  | Kraig Higginson |
|  |  | Chief Executive Officer |
| Date: November 14, 2025 |  |  |

---

## Exhibit 10.1

**Exhibit 10.1**

**PURCHASE AGREEMENT**

**THIS PURCHASE AGREEMENT** (this "<u>Agreement</u>"), dated as of November 11, 2025, is made by and between **ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD** (the "<u>Investor</u>"), and **ASPIRE BIOPHARMA HOLDINGS, INC.,** a Delaware corporation (the "<u>Company</u>").

**WHEREAS**, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to $100.00 million of the Company's common stock, par value $0.001 per share (the "<u>Common Shares</u>"); and

**WHEREAS**, the Common Shares are listed for trading on the Nasdaq Capital Market under the symbol "ASBP"; and

**WHEREAS**, the offer and sale of the Common Shares issuable hereunder will be made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the "<u>Securities Act</u>"), or upon such other exemption from the registration requirements of the Securities Act as may be available with respect to any or all of the transactions to be made hereunder.

**NOW, THEREFORE**, the parties hereto agree as follows:

**ARTICLE I**

**CERTAIN DEFINITIONS**

"<u>Advance</u>" shall mean the portion of the Commitment Amount requested by the Company in an Advance Notice.

"<u>Advance Date</u>" shall mean the 1st Trading Day after expiration of the applicable Pricing Period for each Advance.

"<u>Advance Halt</u>" shall have the meaning set forth in Section 2.05(d).

"<u>Advance Notice</u>" shall mean a written notice in the form of <u>Exhibit A</u> attached hereto to the Investor executed by an officer of the Company or other authorized representative of the Company identified on Schedule 1 hereto and setting forth the amount of an Advance that the Company desires to issue and sell to the Investor.

"<u>Advance Notice Date</u>" shall mean each date the Company delivers (in accordance with Section 2.02 of this Agreement) to the Investor an Advance Notice, subject to the terms of this Agreement.

"<u>Affiliate</u>" shall have the meaning set forth in Section 3.07.

"<u>Agreement</u>" shall have the meaning set forth in the preamble of this Agreement.

"<u>Applicable Laws</u>" shall mean all applicable laws, statutes, rules, regulations, orders, executive orders, directives, policies, guidelines and codes having the force of law, whether local, national, or international, as amended from time to time, including without limitation (i) all applicable laws that relate to money laundering, terrorist financing, financial record keeping and reporting, (ii) all applicable laws that relate to anti-bribery, anti-corruption, books and records and internal controls, including the United States Foreign Corrupt Practices Act of 1977, and (iii) any Sanctions laws.

"<u>Bankruptcy Law</u>" means Title 11, U.S. Code, or any similar federal, state or similar laws for the relief of debtors.

"<u>Black Out Period</u>" shall have the meaning set forth in Section 6.02.

"<u>Business Day</u>" means any day on which the Principal Market or Trading Market is open for trading, including any day on which the Principal Market or Trading Market is open for trading for a period of time less than the customary time.

"<u>Buy-In</u>" shall have the meaning set forth in Section 2.06.

"<u>Buy-In Price</u>" shall have the meaning set forth in Section 2.06.

"<u>Closing</u>" shall have the meaning set forth in Section 2.05.

"<u>Commitment Amount</u>" shall mean $100.00 million of Common Shares, *provided that*, the Company shall not effect any sales under this Agreement and the Investor shall not have the obligation to purchase Common Shares under this Agreement to the extent (but only to the extent) that after giving effect to such purchase and sale the aggregate number of Common Shares issued under this Agreement would exceed 19.99% of the outstanding Common Shares as of the date of this Agreement (the "<u>Exchange Cap</u>"); *provided further that*, the Exchange Cap will not apply if the Company obtains the requisite shareholder approval for issuances in excess of the Exchange Cap ("<u>Shareholder Approval</u>").

"<u>Commitment Fee Shares</u>" shall have the meaning set forth in Section 13.04.

"<u>Commitment Period</u>" shall mean the period commencing on the date hereof and expiring upon the date of termination of this Agreement in accordance with Section 11.02.

"<u>Common Shares</u>" shall have meaning set forth in the recitals of this Agreement.

"<u>Company</u>" shall have the meaning set forth in the preamble of this Agreement.

"<u>Company Indemnitees</u>" shall have the meaning set forth in Section 5.02.

"<u>Condition Satisfaction Date</u>" shall have the meaning set forth in Section 7.01.

"<u>Conversion Cap</u>" means a number of Common Shares equal to 19.99% of the number of shares of Common Stock outstanding as of the date hereof calculated in accordance with the listing standards and rules of the Nasdaq Stock Market, including Rule 5635(d) (or any successor provisions thereof). For the avoidance of doubt, once Shareholder Approval is obtained, the Conversion Cap shall cease to exist.

"<u>Custodian</u>" means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

"<u>DTC</u>" means the Depository Trust Company.

"<u>DWAC Shares</u>" means the Commitment Fee Shares or the Common Shares acquired or purchased by the Investor pursuant to this Agreement (a) that the Investor has resold in a manner described under the caption "Plan of Distribution" in the Registration Statement and otherwise in compliance with this Agreement before the delivery of the Transfer Agent Confirmation regarding the resale of such Commitment Fee Shares or Common Shares (as applicable) in accordance with this Agreement, and (b) about which the Investor has (i) delivered to the Company and the transfer agent to the Company (A) the Transfer Agent Confirmation relating to such Commitment Fee Shares or Common Shares (as applicable) and (B) a customary representation letter from the Investor, and, if requested by the transfer agent, its broker, confirming, among other things, the resale of such Commitment Fee Shares or Common Shares (as applicable) in the manner described in clause (a) of this definition of DWAC Shares (including confirmation of compliance with any relevant prospectus delivery requirements), and (ii) delivered to the transfer agent instructions for the delivery of such Commitment Fee Shares or Common Shares (as applicable) to the account with DTC of the Investor's designated broker-dealer as specified in the Transfer Agent Deliverables, which Commitment Fee Shares or Common Shares (as applicable) will be in the hands of the persons who purchase such Commitment Fee Shares or Common Shares (as applicable) from the Investor in the manner described in clause (a) of this definition of DWAC Shares, freely tradable and transferable without restriction on resale and without stop transfer instructions maintained against the transfer thereof.

"<u>Environmental Laws</u>" shall have the meaning set forth in Section 4.08.

"<u>Exchange Act</u>" shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

"<u>Exchange Cap</u>" has the meaning set forth in the definition of "Commitment Amount".

"<u>Hazardous Materials</u>" shall have the meaning set forth in Section 4.08.

"<u>Indemnified Liabilities</u>" shall have the meaning set forth in Section 5.01.

"<u>Investor</u>" shall have the meaning set forth in the preamble of this Agreement.

"<u>Investor Indemnitees</u>" shall have the meaning set forth in Section 5.01.

"<u>Market Price</u>" shall mean the VWAP of the Common Shares during the Pricing Period.

"<u>Material Adverse Effect</u>" shall mean any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the transactions contemplated herein, (ii) a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect on a timely basis its obligations under this Agreement.

"<u>Material Outside Event</u>" shall have the meaning set forth in Section 6.08.

"<u>Maximum Advance Amount</u>" shall be calculated as follows: (a) if the Advance Notice is received by 8:30 a.m. Eastern Time, the lower of (i) an amount equal to eighty percent (80%) of the average of the Daily Value Traded of the Common Shares on the ten (10) Trading Days immediately preceding an Advance Notice, or (ii) $20 million; (b) if the Advance Notice is received by 10:30 a.m. Eastern Time, the lower of (i) an amount equal to forty percent (40%) of the average of the Daily Value Traded of the Common Shares on the ten (10) Trading Days immediately preceding an Advance Notice, or (ii) $10 million; and (c) if the Advance Notice is received by 12:30 p.m. Eastern Time, the lower of (i) an amount equal to twenty percent (20%) of the average of the Daily Value Traded of the Common Shares on the ten (10) Trading Days immediately preceding an Advance Notice, or (ii) $5 million; provided, however, that the parties hereto may modify the aforementioned conditions by mutual prior written consent. For purposes hereof, "<u>Daily Value Traded</u>" is the product obtained by multiplying the daily trading volume of the Company's Common Shares on the Principal Market or Trading Market during regular trading hours as reported by Bloomberg L.P., by the VWAP for such Trading Day. For the avoidance of doubt, the daily trading volume shall include all trades on the Principal Market or Trading Market during regular trading hours.

"<u>OFAC</u>" shall mean the U.S. Department of Treasury's Office of Foreign Asset Control.

"<u>Ownership Limitation</u>" shall have the meaning set forth in Section 2.04(a).

"<u>Person</u>" shall mean an individual, a corporation, a partnership, a limited liability company, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

"<u>Plan of Distribution</u>" shall mean the section of a Registration Statement disclosing the plan of distribution of the Common Shares.

"<u>Pricing Period</u>" shall mean one (1) Trading Day, as notified by the Company to the Investor in the applicable Advance Notice, commencing on the Advance Notice Date.

"<u>Principal Market</u>" shall mean the Nasdaq Capital Market.

"<u>Purchase Price</u>" shall mean the price per Share obtained by multiplying the Market Price by 96.0%. If the total day's VWAP at the end of any given 1-hour interval has changed by +/- 4% versus the previous 1-hour interval, the Purchase Price will be 96% of the Investor's sale execution for that day. The last 30 minutes of trading on a Trading Day will count as the final "1-hour" interval of such Trading Day.

"<u>Registrable Securities</u>" shall mean (i) the Common Shares, (ii) the Commitment Fee Shares, (iii) the Transaction Fee Shares and (iv) any securities issued or issuable with respect to any of the foregoing by way of exchange, stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise.

"<u>Registration Limitation</u>" shall have the meaning set forth in Section 2.04(b).

"<u>Registration Statement</u>" shall mean a registration statement on Form S-1 or Form S-3 or on such other form promulgated by the SEC for which the Company then qualifies and which counsel for the Company shall deem appropriate, and which form shall be available for the registration of the resale by the Investor of the Registrable Securities under the Securities Act.

"<u>Regulation D</u>" shall mean the provisions of Regulation D promulgated under the Securities Act.

"<u>Required Delivery Date</u>" means any date on which the Company or its transfer agent is required to deliver Common Shares to Investor hereunder.

"<u>Sanctions</u>" means any sanctions administered or enforced by OFAC, the U.S. State Department, the United Nations Security Council, the European Union, Her Majesty's Treasury, or other relevant sanctions authority.

"<u>Sanctions Programs</u>" means any OFAC economic sanction program (including, without limitation, programs related to Crimea, Cuba, Iran, North Korea, Sudan and Syria).

"<u>SEC</u>" shall mean the U.S. Securities and Exchange Commission.

"<u>SEC Documents</u>" shall have the meaning set forth in Section 4.04.

"<u>Securities Act</u>" shall have the meaning set forth in the recitals of this Agreement.

"<u>Securities Purchase Agreement</u>" has the meaning set forth in Section 2.04(c).

"<u>Settlement Document</u>" shall have the meaning set forth in Section 2.05(a).

"<u>Shares</u>" shall mean the Commitment Fee Shares, Transaction Fee Shares and the Common Shares to be issued from time to time hereunder pursuant to an Advance.

"<u>Subsidiaries</u>" shall have the meaning set forth in Section 4.01.

"<u>Trading Day</u>" shall mean any day during which the Principal Market or Trading Market shall be open for business.

"<u>Trading Market</u>" shall mean the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, or the NYSE Euronext, whichever is at the time the principal trading exchange or market for the Common Shares.

"<u>Transaction Documents</u>" shall have the meaning set forth in Section 4.02.

"<u>Transaction Fee Shares</u>" shall have the meaning set forth in Section 13.04(a).

"<u>Transfer Agent Confirmation</u>" shall have the meaning set forth in Section 2.05(b).

"<u>Transfer Agent Deliverables</u>" shall have the meaning set forth in Section 2.05(b).

"<u>VWAP</u>" means, for any Trading Day, the daily volume weighted average price of the Common Shares for such Trading Day on the Principal Market or Trading Market from 9:30 a.m. Eastern Time through 4:00 p.m. Eastern Time, excluding the opening price and the closing price, if the Advance Notice is received before 12:30 p.m. Eastern Time (the "<u>Measurement Period</u>"); provided, however, upon an Advance Halt the VWAP calculation shall terminate as of the effective time of the Material Outside Event.

**ARTICLE II**

**ADVANCES**

**Section 2.01 Advances; Mechanics.** Subject to the terms and conditions of this Agreement (including, without limitation, the provisions of Article VII hereof), the Company at its sole and exclusive option, may issue and sell to the Investor, and the Investor shall purchase from the Company, Common Shares on the following terms.

**Section 2.02 Advance Notice.** At any time during the Commitment Period, the Company may require the Investor to purchase Common Shares by delivering an Advance Notice to the Investor, subject to the conditions set forth in Section 7.01, and in accordance with the following provisions:

(a) The
Company shall, in its sole discretion, select the amount of the Advance, not to exceed the Maximum Advance Amount, it desires to issue
and sell to the Investor in each Advance Notice and the time it desires to deliver each Advance Notice.

(b) There
 shall be no mandatory minimum Advances and no non-usages fee for not utilizing the Commitment Amount or any part thereof.

(c) The
 Company shall be limited to delivering up to two (2) Advance Notices to Investor per Trading Day.

(d) The
 Advance Notice shall be valid upon delivery to Investor in accordance with <u>Exhibit C</u>.

**Section 2.03 Date of Delivery of Advance Notice.** An Advance Notice shall be deemed delivered on the day it is received by the Investor if such notice is received by email prior to 12:30 p.m. Eastern Time (or later if waived by the Investor in its sole discretion) in accordance with the instructions set forth on <u>Exhibit C</u>.

**Section 2.04 Advance Limitations.** Regardless of the amount of an Advance requested by the Company in the Advance Notice, the final amount of an Advance pursuant to an Advance Notice shall be reduced in accordance with each of the following limitations:

(a) <u>Ownership Limitation; Commitment Amount</u>. In no event shall the number of Common Shares issuable to the Investor pursuant to an Advance cause
the aggregate number of Shares beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act) by the Investor and its
Affiliates as a result of previous issuances and sales of Common Shares to Investor under this Agreement to exceed 9.99% of the then
outstanding Common Shares (the " <u>Ownership Limitation</u> "). In connection with each Advance Notice delivered by the Company,
any portion of an Advance that would (i) cause the Investor to exceed the Ownership Limitation or (ii) cause the aggregate number of
Common Shares issued and sold to the Investor hereunder to exceed the Commitment Amount shall automatically be withdrawn with no further
action required by the Company, and such Advance Notice shall be deemed automatically modified to reduce the amount of the Advance requested
by an amount equal to such withdrawn portion; provided that in the event of any such automatic withdrawal and automatic modification,
Investor will promptly notify the Company of such event.

(b) <u>Registration Limitation</u>. In no event shall an Advance exceed the amount registered under the Registration Statement then in effect (the
 " <u>Registration Limitation</u> ") or the Exchange Cap to the extent applicable. In connection with each Advance Notice,
 any portion of an Advance that would exceed the Registration Limitation or Exchange Cap shall automatically be withdrawn with no
 further action required by the Company and such Advance Notice shall be deemed automatically modified to reduce the aggregate amount
 of the requested Advance by an amount equal to such withdrawn portion in respect of each Advance Notice; provided that in the
 event of any such automatic withdrawal and automatic modification, Investor will promptly notify the Company of such event.

(c) <u>Principal Market Regulation</u>. The Company shall not effect any sales of Common Shares under this Agreement and the Investor shall not have the
obligation to purchase Common Shares under this Agreement to the extent (but only to the extent) that after giving effect to such purchase
and sale the aggregate number of Common Shares issued under this Agreement including the Commitment Fee Shares, plus the Common Shares
issued pursuant to that certain securities purchase agreement entered into by the Company and Investor on or about the date of this Agreement
(the " <u>Securities Purchase Agreement</u> "), and Common Shares issued pursuant to the Notes (as defined in the Securities
Purchase Agreement), and Common Shares issued pursuant to the Warrants (as defined in the Securities Purchase Agreement) would exceed
the Conversion Cap, subject to appropriate adjustment for any stock dividend, stock split, stock combination, rights offerings, reclassification
or similar transaction that proportionately decreases or increases the Common Shares until the Shareholder Approval has been obtained
by the Company. For the avoidance of any doubt, this prohibition shall not apply to the issuance of the Commitment Fee Shares.

(d) Notwithstanding
 any other provision in this Agreement, the Company and the Investor acknowledge and agree that upon the Investor's receipt
 of a valid Advance Notice the parties shall be deemed to have entered into an unconditional contract binding on both parties for
 the purchase and sale of Common Shares pursuant to such Advance Notice in accordance with the terms of this Agreement and subject
 to Applicable Law and Section 3.08 (Trading Activities), the Investor may sell Common Shares during the Pricing Period.

**Section 2.05 Closings.** The closing of each Advance and each sale and purchase of Common Shares related to each Advance (each, a "<u>Closing</u>") shall take place as soon as practicable on or after each Advance Date in accordance with the procedures set forth below. The parties acknowledge that the Purchase Price is not known at the time the Advance Notice is delivered (at which time the Investor is irrevocably bound) but shall be determined on each Closing based on the daily prices of the Common Shares that are the inputs to the determination of the Purchase Price as set forth further below. In connection with each Closing, the Company and the Investor shall fulfill each of its obligations as set forth below:

(a) On
 each Advance Date, the Investor shall deliver to the Company a written document, in the form attached hereto as <u>Exhibit B</u> (each a " <u>Settlement Document</u> "), setting forth the final number of Common Shares to be purchased by the Investor
 (taking into account any adjustments pursuant to <u>Section 2.04</u>), the Market Price, the Purchase Price, the aggregate proceeds
 to be paid by the Investor to the Company, and a report by Bloomberg, L.P. indicating the VWAP for each of the Trading Days during
 the Pricing Period (or, if not reported on Bloomberg, L.P., another reporting service reasonably agreed to by the parties), in each
 case in accordance with the terms and conditions of this Agreement.

(b) Promptly
after receipt of the Settlement Document with respect to each Advance (and, in any event, not later than one (1) Trading Days after such
receipt), the Company will, or will cause its transfer agent to, issue in the Investor's name in a DRS account or accounts at the
transfer agent all Common Shares purchased by Investor pursuant to such Advance. Such Common Shares shall constitute "restricted
securities" as such term is defined in Rule 144(a)(3) under the Securities Act and the certificate or book- entry statement representing
such Shares shall bear the restrictive legend under the Securities Act set forth in Section 9.1(iii). Notwithstanding the foregoing,
if the Investor has resold the Common Shares in a manner described under the caption "Plan of Distribution" in the Registration
Statement and otherwise in compliance with this Agreement prior to the delivery by the Investor to the Company of the Settlement Document,
the Investor shall concurrently with the delivery by the Investor to the Company of such Settlement Document (i) send a confirmation
to the transfer agent setting forth the number of such Common Shares that have been so resold and the date of such resales (such confirmation,
the " <u>Transfer Agent Confirmation</u> ") and (ii) deliver to the transfer agent the items set forth in clause (b) of the
definition of DWAC Shares with respect to such resold Common Shares and such other items as the transfer agent may reasonably request
(collectively, the " <u>Transfer Agent Deliverables</u> "). With respect to Common Shares or Commitment Fee Shares resold by
the Investor as described in the preceding sentence and as to which the Investor has timely delivered the Transfer Agent Deliverables
with respect to such resold Common Shares or Commitment Fee Shares, such securities shall be delivered and credited by the transfer agent
using the Fast Automated Securities Transfer (FAST) Program maintained by DTC (or any similar program hereafter adopted by DTC performing
substantially the same function) to the account with DTC of the Investor's designated Broker-Dealer as specified in the Transfer
Agent Deliverables with respect to such resold securities at the time such securities would otherwise have been required to be delivered
to the Investor in accordance with this Agreement, which securities (x) shall only be used by the Investor's Broker-Dealer to deliver
such securities to DTC for the purpose of settling the Investor's share delivery obligations with respect to the sale of such Common
Shares or Commitment Fee Shares (as applicable), which may include delivery to other accounts of such Broker-Dealer and inclusion in
the number of Common Shares or Commitment Fee Shares delivered by that Broker-Dealer in "net settling" that Broker- Dealer's
trading of shares of the Company's Common Shares, including its positions with the Broker- Dealers of the respective persons who
purchase such securities from the Investor, and (y) shall remain "restricted securities" as such term is defined in Rule
144(a)(3) under the Securities Act until so delivered. The Company and the Investor acknowledge that the Investor shall be prohibited
from selling Shares representing more than 15% of the Daily Value Traded on any Trading Day unless otherwise agreed by the Company and
the Investor in writing and provided that the Company is not in material default under this Agreement. The Company and the Investor acknowledge
that, if and when the Investor has (i) resold Commitment Fee Shares or Common Shares in a manner described under the caption "Plan
of Distribution" in the Registration Statement and otherwise in compliance with this Agreement and (ii) timely delivered the Transfer
Agent Deliverables with respect to such resold Commitment Fee Shares or Common Shares (as applicable), the transfer agent shall cause
such resold Commitment Fee Shares or Common Shares (as applicable) to be subsequently credited using the Fast Automated Securities Transfer
(FAST) Program maintained by DTC (or any similar program hereafter adopted by DTC performing substantially the same function) to the
account with DTC of the Investor's designated Broker-Dealer as specified in the Transfer Agent Deliverables with respect to such
resold Commitment Fee Shares or Common Shares (as applicable), which Commitment Fee Shares or Common Shares (as applicable) (x) shall
only be used by the Investor's Broker-Dealer to deliver such resold Commitment Fee Shares or Common Shares (as applicable) to DTC
for the purpose of settling the Investor's share delivery obligations with respect to the sale of such Common Shares or Commitment
Fee Shares (as applicable), which may include delivery to other accounts of such Broker-Dealer and inclusion in the number of securities
delivered by that Broker-Dealer in "net settling" that Broker-Dealer's trading of shares of the Company's Common
Shares, including its positions with the Broker-Dealers of the respective persons who purchase such Commitment Shares or Shares (as applicable)
from the Investor, and (y) shall remain "restricted securities" as such term is defined in Rule 144(a)(3) under the Securities
Act until so delivered. The Company and the Investor acknowledge that such resold Commitment Fee Shares or Common Shares (as applicable)
credited to the account with DTC of the Investor's designated Broker-Dealer shall be eligible for transfer to the third-party purchasers
of such Commitment Fee Shares or Common Shares or their respective Broker-Dealers as DWAC Shares. The Company and the Investor acknowledge
that such resold Commitment Fee Shares or Common Shares (as applicable) credited to the account with DTC of the Investor's designated
Broker-Dealer shall be eligible for transfer to the third-party purchasers of such Commitment Fee Shares or Common Shares or their respective
Broker-Dealers as DWAC Shares. The Company shall promptly notify Investor if it has reasonable grounds to dispute the calculations set
forth in the Settlement Document, and the Company agrees that such calculations shall be deemed agreed upon and final upon transfer of
the Common Shares. Promptly upon receipt of such notification (in any event, not later than three (3) Trading Days after such receipt),
the Investor shall pay to the Company the aggregate purchase price of the Common Shares (as set forth in the Settlement Document) in
cash in immediately available funds to an account designated by the Company in writing and transmit notification to the Company that
such funds transfer has been requested. No fractional shares shall be issued, and any fractional amounts shall be rounded to the next
higher whole number of shares.

(c) On
 or prior to the Advance Date, each of the Company and the Investor shall deliver to the other all documents, instruments and
 writings expressly required to be delivered by either of them pursuant to this Agreement in order to implement and effect the
 transactions contemplated herein.

(d) Notwithstanding
anything to the contrary in this Agreement, if on any day during the Pricing Period (i) the Company notifies Investor that a Material
Outside Event set forth in Section 6.08(i) through (v) has occurred or if the Material Outside Event set forth in Sections 6.08(vi) or
(vii) shall have occurred, or (ii) the Company notifies the Investor of a Black Out Period, the parties agree that the pending Advance
shall end (the " <u>Advance Halt</u> ") and the final number of Common Shares to be purchased by the Investor at the Closing
for such Advance shall be equal to the number of Common Shares sold by the Investor during the applicable Pricing Period prior to the
notification from the Company of a Material Outside Event or Black Out Period.

**Section 2.06 Failure to Timely Deliver.**

(a) If
 on or prior to the Required Delivery Date either (I) if the transfer agent is not participating in the DTC Fast Automated Securities
 Transfer Program, the Company shall fail to issue and deliver a certificate to Investor and register such Common Shares on the
 Company's share register or, if the transfer agent is participating in the DTC Fast Automated Securities Transfer Program,
 credit the balance account of Investor or Investor's designee with DTC for the number of Common Shares to which Investor
 submitted for legend removal by Investor pursuant to clause (ii) below or otherwise or (II) if the Company's transfer agent is
 participating in the DTC Fast Automated Securities Transfer Program, the transfer agent fails to credit the balance account of
 Investor or Investor's designee with DTC for any Common Shares submitted for legend removal by Investor, in each case, if and
 only if the Investor has delivered the Transfer Agent Deliverables in accordance with the requirements of Section 2.05(b) above, and
 the Company fails to promptly, but in no event later than one (1) Business Day (x) so notify Investor and (y) deliver the Common
 Shares electronically without any restrictive legend in accordance with the requirements of Section 2.05(b) above, and if on or
 after such Trading Day Investor purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a
 sale by Investor of Common Shares submitted for legend removal by Investor that Investor is entitled to receive from the Company (a
 " <u>Buy- In</u> "), then the Company shall, within one (1) Business Day after Investor's request and in
 Investor's discretion, either (i) pay cash to Investor in an amount equal to Investor's total purchase price (including
 brokerage commissions, borrow fees and other out-of-pocket expenses, if any, for the Common Shares so purchased) (the
 " <u>Buy-In Price</u> "), at which point the Company's obligation to so deliver such certificate or credit
 Investor's balance account shall terminate and such shares shall be cancelled, or (ii) promptly honor its obligation to so
 deliver to Investor a certificate or certificates or credit the balance account of Investor or Investor's designee with DTC
 representing such number of Common Shares that would have been so delivered if the Company timely complied with its obligations
 hereunder and pay cash to Investor in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number
 of Common Shares that the Company was required to deliver to Investor by the Required Delivery Date multiplied by (B) the price at
 which Investor sold such Common Shares in anticipation of the Company's timely compliance with its delivery obligations
 hereunder. Nothing shall limit Investor's right to pursue any other remedies available to it hereunder, at law or in equity,
 including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure
 to timely deliver certificates representing Common Shares (or to electronically deliver such Common Shares) as required pursuant to
 the terms hereof.

(b) In
 the event the Investor sells Common Shares after receipt of an Advance Notice and the Company fails to perform its obligations as
 mandated in Section 2.05, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in
 Article V hereto and in addition to any other remedy to which the Investor is entitled at law or in equity, including, without
 limitation, specific performance, it will hold the Investor harmless against any loss, claim, damage, or expense (including, without
 limitation, all brokerage commissions, borrow fees, legal fees and expenses and all other related out-of-pocket expenses), as
 incurred, arising out of or in connection with such default by the Company and acknowledges that irreparable damage may occur in the
 event of any such default. It is accordingly agreed that the Investor shall be entitled to an injunction or injunctions to prevent
 such breaches of this Agreement and to specifically enforce (subject to the Securities Act and other rules of the Principal Market
 or Trading Market), without the posting of a bond or other security, the terms and provisions of this Agreement.

(c) In
 the event the Company provides an Advance Notice and the Investor fails to perform its obligations as mandated in Section 2.05, the
 Investor agrees that in addition to and in no way limiting the rights and obligations set forth in Article V hereto and in addition
 to any other remedy to which the Company is entitled at law or in equity, including, without limitation, specific performance, it
 will hold the Company harmless against any loss, claim, damage, or expense (including, without limitation, legal fees and expenses
 and all other related out-of-pocket expenses), as incurred, arising out of or in connection with such default by the Investor and
 acknowledges that irreparable damage may occur in the event of any such default. It is accordingly agreed that the Company shall be
 entitled to an injunction or injunctions to prevent such breaches of this Agreement and to specifically enforce (subject to the
 Securities Act and other rules of the Principal Market or Trading Market), without the posting of a bond or other security, the
 terms and provisions of this Agreement.

**Section 2.07 Completion of Resale Pursuant to the Registration Statement.** After the Investor has purchased the full Commitment Amount and has completed the subsequent resale of all of the Registrable Securities (which shall include all of the Commitment Fee Shares), Investor will notify the Company that all subsequent resales are completed and the Company will be under no further obligation to maintain the effectiveness of the Registration Statement.

**ARTICLE III**

**REPRESENTATIONS AND WARRANTIES OF INVESTOR**

Investor hereby represents and warrants to, and agrees with, the Company that the following are true and correct as of the date hereof and as of each Advance Notice Date and each Advance Date:

**Section 3.01 Organization and Authorization.** The Investor is duly organized, validly existing and in good standing under the laws of the Cayman Islands and has all requisite power and authority to execute, deliver and perform this Agreement, including all transactions contemplated hereby. The decision to invest and the execution and delivery of this Agreement by the Investor, the performance by the Investor of its obligations hereunder and the consummation by the Investor of the transactions contemplated hereby have been duly authorized and require no other proceedings on the part of the Investor. The undersigned has the right, power and authority to execute and deliver this Agreement and all other instruments on behalf of the Investor or its shareholders. This Agreement has been duly executed and delivered by the Investor and, assuming the execution and delivery hereof and acceptance thereof by the Company, will constitute the legal, valid and binding obligations of the Investor, enforceable against the Investor in accordance with its terms.

**Section 3.02 Evaluation of Risks.** The Investor has such knowledge and experience in financial, tax and business matters as to be capable of evaluating the merits and risks of, and bearing the economic risks entailed by, an investment in the Common Shares of the Company and of protecting its interests in connection with the transactions contemplated hereby. The Investor acknowledges and agrees that its investment in the Company involves a high degree of risk, and that the Investor may lose all or a part of its investment.

**Section 3.03 No Legal, Investment or Tax Advice from the Company.** The Investor acknowledges that it had the opportunity to review this Agreement and the transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying solely on such counsel and advisors and not on any statements or representations of the Company or any of the Company's representatives or agents for legal, tax, investment or other advice with respect to the Investor's acquisition of Common Shares hereunder, the transactions contemplated by this Agreement or the laws of any jurisdiction, and the Investor acknowledges that the Investor may lose all or a part of its investment.

**Section 3.04 Investment Purpose.** The Investor is acquiring the Common Shares for its own account, for investment purposes and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under or exempt from the registration requirements of the Securities Act; provided, however, that by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with, or pursuant to, a registration statement filed pursuant to this Agreement or an applicable exemption under the Securities Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to sell or distribute any of the Common Shares. The Investor acknowledges that it will be disclosed as an "underwriter" and a "selling stockholder" in each Registration Statement and in any prospectus contained therein.

**Section 305. Accredited Investor.** The Investor is an "Accredited Investor" as that term is defined in Rule 501(a)(3) of Regulation D.

**Section 3.06 Information.** The Investor and its advisors (and its counsel), if any, have been furnished with all materials relating to the business, finances and operations of the Company and information the Investor deemed material to making an informed investment decision. The Investor and its advisors (and its counsel), if any, have been afforded the opportunity to ask questions of the Company and its management and have received answers to such questions. Neither such inquiries nor any other due diligence investigations conducted by such Investor or its advisors (and its counsel), if any, or its representatives shall modify, amend or affect the Investor's right to rely on the Company's representations and warranties contained in this Agreement. The Investor acknowledges and agrees that the Company has not made to the Investor, and the Investor acknowledges and agrees it has not relied upon, any representations and warranties of the Company, its employees or any third party other than the representations and warranties of the Company contained in this Agreement. The Investor understands that its investment involves a high degree of risk. The Investor has sought such accounting, legal and tax advice, as it has considered necessary to make an informed investment decision with respect to the transactions contemplated hereby.

**Section 3.07 Not an Affiliate.** The Investor is not an officer, director or a person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with the Company or any "affiliate" of the Company (as that term is defined in Rule 405 promulgated under the Securities Act).

**Section 3.08 Trading Activities.** The Investor's trading activities with respect to the Common Shares shall be in compliance with all applicable federal and state securities laws, rules and regulations and the rules and regulations of the Principal Market or Trading Market. Neither the Investor nor its affiliates has any open short position in the Common Shares, nor has the Investor entered into any hedging transaction that establishes a net short position with respect to the Common Shares, and the Investor agrees that it shall not, and that it will cause its affiliates not to, engage in any short sales or hedging transactions with respect to the Common Shares; provided that the Company acknowledges and agrees that upon receipt of an Advance Notice the Investor has the right to sell (a) the Common Shares to be issued to the Investor pursuant to the Advance Notice prior to receiving such Common Shares, or (b) other Common Shares issued or sold by the Company to Investor pursuant to this Agreement and which the Company has continuously held as a long position.

**Section 3.09 General Solicitation.** Neither the Investor, nor any of its affiliates, nor any person acting on its or their behalf, has engaged or will engage in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with any offer or sale of the Common Shares by the Investor.

**ARTICLE IV**

**REPRESENTATIONS AND WARRANTIES OF THE COMPANY**

Except as set forth in the SEC Documents, the Company represents and warrants to the Investor that, as of the date hereof and each Advance Notice Date (other than representations and warranties which address matters only as of a certain date, which shall be true and correct as written as of such certain date), that:

**Section 4.01 Organization and Qualification.** Each of the Company and its Subsidiaries (as defined below) is an entity duly organized and validly existing under the laws of its state of organization or incorporation, and has the requisite power and authority to own its properties and to carry on its business as now being conducted. Each of the Company and its Subsidiaries is duly qualified to do business and is in good standing (to the extent applicable) in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. The Company's Subsidiaries any Person (as defined below) in which the Company, directly or indirectly, (x) owns a majority of the outstanding capital stock or equity or similar interests of such Person or (y) controls or operates all or any part of the business, operations or administration of such Person.

**Section 4.02 Authorization, Enforcement, Compliance with Other Instruments.** The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Shares in accordance with the terms hereof and thereof. The execution and delivery by the Company of this Agreement and the other Transaction Documents, and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) have been or (with respect to consummation) will be duly authorized by the Company's board of directors and no further consent or authorization will be required by the Company, its board of directors or its shareholders (except as otherwise contemplated by this Agreement). This Agreement and the other Transaction Documents to which it is a party have been (or, when executed and delivered, will be) duly executed and delivered by the Company and, assuming the execution and delivery thereof and acceptance by the Investor, constitute (or, when duly executed and delivered, will be) the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or other laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies and except as rights to indemnification and to contribution may be limited by applicable foreign, federal or U.S. state securities law. "<u>Transaction Documents</u>" means, collectively, this Agreement and each of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

**Section 4.03 No Conflict.** The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) will not (i) result in a violation of the articles of incorporation or other organizational documents of the Company or its Subsidiaries (with respect to consummation, as the same may be amended prior to the date on which any of the transactions contemplated hereby are consummated), (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or its Subsidiaries or by which any property or asset of the Company or its Subsidiaries is bound or affected except, in the case of clause (ii) or (iii) above, to the extent such violations or conflicts would not reasonably be expected to have a Material Adverse Effect.

**Section 4.04 SEC Documents; Financial Statements.** The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the Exchange Act for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (all of the foregoing filed within the past two years preceding the date hereof or amended after the date hereof, or filed after the date hereof, and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, and all registration statements filed by the Company under the Securities Act, being hereinafter referred to as the "<u>SEC Documents</u>"). The Company has made available to the Investor through the SEC's website at http://www.sec.gov, true and complete copies of the SEC Documents, and none of the SEC Documents, when viewed as a whole as of the date hereof, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates (or, with respect to any filing that has been amended or superseded, the date of such amendment or superseding filing), the SEC Documents complied in all material respects with the requirements of the Exchange Act or the Securities Act, as applicable, and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents. As of their respective dates (or, with respect to any financial statements that have been amended or superseded, the date of such amended or superseding financial statements), the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the respective dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).

**Section 4.05 Equity Capitalization.** As of November 10, 2025, the authorized capital of the Company consists of 490,000,000 common shares, par value $0.0001 per share, of which 79,896,761 are issued and outstanding, and 5,000,000 preferred shares, par value $0.0001 per share, of which none are issued and outstanding.

**Section 4.06 Intellectual Property Rights.** The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and rights, if any, necessary to conduct their respective businesses as now conducted, except as would not cause a Material Adverse Effect. The Company and its Subsidiaries have not received written notice of any infringement by the Company or its Subsidiaries of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, or trade secrets. To the knowledge of the Company, there is no claim, action or proceeding being made or brought against, or to the Company's knowledge, being threatened against the Company or its Subsidiaries regarding any material trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other infringement; and the Company is not aware of any facts or circumstances which might give rise to any of the foregoing.

**Section 4.07 Employee Relations.** Neither the Company nor any of its Subsidiaries is involved in any labor dispute nor, to the knowledge of the Company or any of its Subsidiaries, is any such dispute threatened, in each case which is reasonably likely to cause a Material Adverse Effect.

**Section 4.08 Environmental Laws.** The Company and its Subsidiaries (i) have not received written notice alleging any failure to comply in all material respects with all Environmental Laws (as defined below), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) have not received written notice alleging any failure to comply with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term "<u>Environmental Laws</u>" means all applicable foreign, federal, U.S. state and local laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, "<u>Hazardous Materials</u>") into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

**Section 4.09 Title.** Except as would not cause a Material Adverse Effect, the Company (or its Subsidiaries) have indefeasible fee simple or leasehold title to its properties and assets owned by it, free and clear of any pledge, lien, security interest, encumbrance, claim or equitable interest. Any real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries.

**Section 4.10 Insurance.** The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

**Section 4.11 Regulatory Permits.** Except as would not cause a Material Adverse Effect, the Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to own their respective businesses, and neither the Company nor any such Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permits.

**Section 4.12 Internal Accounting Controls.** The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management's general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences, and management is not aware of any material weaknesses that are not disclosed in the SEC Documents as and when required.

**Section 4.13 Absence of Litigation.** Except with respect to receipt of deficiency notices relating to Nasdaq delisting, which have been disclosed in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending against or affecting the Company, the Common Shares or any of the Company's Subsidiaries, wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect.

**Section 4.14 Subsidiaries.** As of the date hereof, the Company does not own or control, directly or indirectly, any interest in any other corporation, partnership, association or other business entity, except for the Subsidiaries.

**Section 4.15 Tax Status.** Except as would not have a Material Adverse Effect, each of the Company and its Subsidiaries (i) has timely made or filed all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. The Company has not received written notification any unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company and its Subsidiaries know of no basis for any such claim where failure to pay would cause a Material Adverse Effect.

**Section 4.16 Certain Transactions.** Except as (i) set forth in the SEC Documents or (ii) not required to be disclosed pursuant to Applicable Law (including, for the avoidance of doubt, not yet required to be disclosed at the relevant time), none of the officers or directors of the Company is presently a party to any transaction with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer or director, or to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer or director has a substantial interest or is an officer, director, trustee or partner.

**Section 4.17 Rights of First Refusal.** The Company is not obligated to offer the Common Shares offered hereunder on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former shareholders of the Company, underwriters, brokers, agents or other third parties.

**Section 4.18 Dilution.** The Company is aware and acknowledges that the issuance of Common Shares hereunder could cause dilution to existing shareholders and could significantly increase the outstanding number of Common Shares.

**Section 4.19 Acknowledgment Regarding Investor's Purchase of Shares.** The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm's length investor with respect to this Agreement and the transactions contemplated hereunder. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereunder and any advice given by the Investor or any of its representatives or agents in connection with this Agreement and the transactions contemplated hereunder is merely incidental to the Investor's purchase of the Shares hereunder. The Company is aware and acknowledges that it shall not be able to request Advances under this Agreement if the Registration Statement is not effective or if any issuances of Common Shares pursuant to any Advances would violate any rules of the Principal Market or Trading Market.

**Section 4.20 Sanctions Matters.** Neither the Company, nor any Subsidiary of the Company, nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary of the Company, is a Person that is, or is owned or controlled by a Person that is on the list of Specially Designated Nationals and Blocked Persons maintained by OFAC from time to time;

(a) the
 subject of any Sanctions; or

(b) has
 a place of business in, or is operating, organized, resident or doing business in a country or territory that is, or whose
 government is, the subject of Sanctions Programs (including without limitation Crimea, Cuba, Iran, North Korea, Sudan and
 Syria).

**Section 4.21 DTC Eligibility**. The Company, through the transfer agent, currently participates in the DTC Fast Automated Securities Transfer (FAST) Program and the Common Shares can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program.

**ARTICLE V**

**INDEMNIFICATION**

The Investor and the Company represent to the other the following with respect to itself:

**Section 5.01 Indemnification by the Company.** In consideration of the Investor's execution and delivery of this Agreement, and in addition to all of the Company's other obligations under this Agreement, the Company shall defend, protect, indemnify and hold harmless the Investor, its investment manager, and each of their respective officers, directors, managers, members, partners, employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) and each person who controls the Investor within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the "<u>Investor Indemnitees</u>") from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and reasonable and documented expenses in connection therewith (irrespective of whether any such Investor Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys' fees and disbursements (the "<u>Indemnified Liabilities</u>"), incurred by the Investor Indemnitees or any of them as a result of, or arising out of, or relating to (a) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; <u>provided</u>, <u>however</u>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor specifically for inclusion therein; (b) any material misrepresentation or breach of any material representation or material warranty made by the Company in this Agreement or any other certificate, instrument or document contemplated hereby or thereby; or (c) any material breach of any material covenant, material agreement or material obligation of the Company contained in this Agreement or any other certificate, instrument or document contemplated hereby or thereby. To the extent that the foregoing undertaking by the Company may be unenforceable under Applicable Law, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under Applicable Law.

**Section 5.02 Indemnification by the Investor.** In consideration of the Company's execution and delivery of this Agreement, and in addition to all of the Investor's other obligations under this Agreement, the Investor shall defend, protect, indemnify and hold harmless the Company and all of its officers, directors, shareholders, employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) and each person who controls the Investor within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the "<u>Company Indemnitees</u>") from and against any and all Indemnified Liabilities incurred by the Company Indemnitees or any of them as a result of, or arising out of, or relating to (a) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that the Investor will only be liable for written information relating to the Investor furnished to the Company by or on behalf of the Investor specifically for inclusion in the documents referred to in the foregoing indemnity, and will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Investor by or on behalf of the Company specifically for inclusion therein; (b) any misrepresentation or breach of any representation or warranty made by the Investor in this Agreement or any instrument or document contemplated hereby or thereby executed by the Investor; or (c) any breach of any covenant, agreement or obligation of the Investor(s) contained in this Agreement or any other certificate, instrument or document contemplated hereby or thereby executed by the Investor. To the extent that the foregoing undertaking by the Investor may be unenforceable under Applicable Law, the Investor shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under Applicable Law.

**Section 5.03 Notice of Claim.** Promptly after receipt by an Investor Indemnitee or Company Indemnitee of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving an Indemnified Liability, such Investor Indemnitee or Company Indemnitee, as applicable, shall, if a claim for an Indemnified Liability in respect thereof is to be made against any indemnifying party under this Article V, deliver to the indemnifying party a written notice of the commencement thereof; but the failure to so notify the indemnifying party will not relieve it of liability under this Article V except to the extent the indemnifying party is prejudiced by such failure. The indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually reasonably satisfactory to the indemnifying party and the Investor Indemnitee or Company Indemnitee, as the case may be; provided, however, that an Investor Indemnitee or Company Indemnitee shall have the right to retain its own counsel with the actual and reasonable third party fees and expenses of not more than one counsel for such Investor Indemnitee or Company Indemnitee to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Investor Indemnitee or Company Indemnitee and the indemnifying party would be inappropriate due to actual or potential differing interests between such Investor Indemnitee or Company Indemnitee and any other party represented by such counsel in such proceeding. The Investor Indemnitee or Company Indemnitee shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Investor Indemnitee or Company Indemnitee which relates to such action or claim. The indemnifying party shall keep the Investor Indemnitee or Company Indemnitee reasonably apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Investor Indemnitee or Company Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Investor Indemnitee or Company Indemnitee of a release from all liability in respect to such claim or litigation. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Investor Indemnitee or Company Indemnitee with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The indemnification required by this Article V shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received and payment therefor is due, subject to receipt by the indemnifying party of an undertaking to repay any amounts that such party is ultimately not entitled to receive as indemnification pursuant to this Agreement.

**Section 5.04 Remedies.** The remedies provided for in this Article V are not exclusive and shall not limit any right or remedy which may be available to any indemnified person at law or equity. The obligations of the parties to indemnify or make contribution under this Article V shall survive expiration or termination of this Agreement.

**Section 5.05 Limitation of Liability.** Notwithstanding the foregoing, no party shall be entitled to recover from the other party for punitive, indirect, incidental or consequential damages.

**ARTICLE VI**

**COVENANTS**

**Section 6.01 Registration Statement.**

(a) <u>Filing of a Registration Statement</u>. No later than ten (10) Business Days following the date hereof, the Company shall have prepared and
 filed with the SEC a Registration Statement for the resale by the Investor of Registrable Securities and shall file one or more
 additional Registration Statements for the resale by Investor of Registrable Securities if necessary. In the event that the
 government remains shut down on the filing date, the Registration Statement shall not contain the delaying amendment language in
 order for the Registration Statement to go effective without any SEC interaction in accordance with Section 8(a) of the Securities
 Act The Company acknowledges and agrees that it shall not have the ability to request any Advances until the effectiveness of a
 Registration Statement registering the applicable Registrable Securities for resale by the Investor. The Company and the Investor
 shall mutually agree on a good faith estimate of the aggregate number of Commitment Fee Shares which may be issuable pursuant to
 Section 13.04 for purposes of registration; provided, however, that in the event such estimated number of shares have been (i)
 underestimated, the Company shall use reasonable best efforts to register additional Commitment Fee Shares promptly after such
 underestimation is made known to the Company and (ii) overestimated, the Company shall treat (and disclose in the registration
 statement the same) such excess shares as Common Shares issuable and saleable to the Investor pursuant to Advances
 hereunder.

(b) <u>Maintaining a Registration Statement</u>. The Company shall use commercially reasonable efforts to maintain the effectiveness of any
 Registration Statement that has been declared effective at all times during the Commitment Period, provided, however, that if the
 Company has received notification pursuant to Section 2.07 that the Investor has completed resales pursuant to the Registration
 Statement for all of the Registrable Securities registered thereon, then the Company shall be under no further obligation to
 maintain the effectiveness of the Registration Statement (provided, however, that if there are Commitment Fee Shares which have not
 yet been issued, the Company shall continue to have the obligation to register such shares and maintain such Registration Statement
 until Investor has sold all of its Commitment Fee Shares). Notwithstanding anything to the contrary contained in this Agreement, the
 Company shall use commercially reasonable efforts to ensure that, when filed, each Registration Statement (including, without
 limitation, all amendments and supplements thereto) and the prospectus (including, without limitation, all amendments and
 supplements thereto) used in connection with such Registration Statement shall not contain any untrue statement of a material fact
 or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of
 prospectuses, in the light of the circumstances in which they were made) not misleading. During the Commitment Period, the Company
 shall notify the Investor promptly if (i) the Registration Statement shall cease to be effective under the Securities Act, (ii) the
 Common Shares shall cease to be authorized for listing on the Principal Market or Trading Market, (iii) the Common Shares cease to
 be registered under Section 12(b) or Section 12(g) of the Exchange Act or (iv) the Company fails to file in a timely manner all
 reports and other documents required of it as a reporting company under the Exchange Act.

(c) <u>Filing Procedures</u>. Not less than one business day prior to the filing of a Registration Statement and not less than one business day
 prior to the filing of any related amendments and supplements to any Registration Statements (except for any amendments or
 supplements caused by the filing of any annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K,
 and any similar or successor reports), the Company shall furnish to the Investor copies of all such documents proposed to be filed,
 which documents (other than those filed pursuant to Rule 424 promulgated under the Securities Act) will be subject to the reasonable
 and prompt review of the Investor (in each of which cases, if such document contains material non-public information as consented to
 by the Investor pursuant to Section 6.13, the information provided to Investor will be kept strictly confidential until filed and
 treated as subject to Section 6.08). The Investor shall furnish comments on a Registration Statement and any related amendment and
 supplement to a Registration Statement to the Company within 24 hours of the receipt thereof. If the Investor fails to provide
 comments to the Company within such 24-hour period, then the Registration Statement, related amendment or related supplement, as
 applicable, shall be deemed accepted by the Investor in the form originally delivered by the Company to the Investor.

(d) <u>Delivery of Final Documents</u>. The Company shall furnish to the Investor without charge, (i) at least one copy of each Registration Statement
as declared effective by the SEC and any amendment(s) thereto, including financial statements and schedules, all documents incorporated
therein by reference, all exhibits and each preliminary prospectus, (ii) at the request of the Investor, at least one copy of the final
prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the
Investor may reasonably request) and (iii) such other documents as the Investor may reasonably request from time to time in order to
facilitate the disposition of the Common Shares owned by the Investor pursuant to a Registration Statement. Filing of the forgoing with
the SEC via its EDGAR system shall satisfy the requirements of this section.

(e) <u>Amendments and Other Filings</u>. The Company shall use commercially reasonable efforts to (i) prepare
 and file with the SEC such amendments (including post-effective amendments) and supplements
 to a Registration Statement and the related prospectus used in connection with such Registration
 Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities
 Act, as may be necessary to keep such Registration Statement effective at all times during
 the Commitment Period, and prepare and file with the SEC such additional Registration Statements
 in order to register for resale under the Securities Act all of the Registrable Securities;
 (ii) cause the related prospectus to be amended or supplemented by any required prospectus
 supplement (subject to the terms of this Agreement), and as so supplemented or amended to
 be filed pursuant to Rule 424 promulgated under the Securities Act; (iii) provide the Investor
 copies of all correspondence from and to the SEC relating to a Registration Statement (provided
 that the Company may excise any information contained therein which would constitute material
 non-public information), and (iv) comply with the provisions of the Securities Act with respect
 to the disposition of all Common Shares of the Company covered by such Registration Statement
 until such time as all of such Common Shares shall have been disposed of in accordance with
 the intended methods of disposition by the seller or sellers thereof as set forth in such
 Registration Statement. In the case of amendments and supplements to a Registration Statement
 which are required to be filed pursuant to this Agreement (including pursuant to this Section
 6.01(e)) by reason of the Company's filing a report on Form 10-K, Form 10-Q or Form
 8-K or any analogous report under the Exchange Act, the Company shall use commercially reasonable
 efforts to file such report in a prospectus supplement filed pursuant to Rule 424 promulgated
 under the Securities Act to incorporate such filing into the Registration Statement, if applicable,
 or shall file such amendments or supplements with the SEC either on the day on which the Exchange Act report is filed
 which created the requirement for the Company to amend or supplement the Registration Statement,
 if feasible, or otherwise promptly thereafter.

(f) <u>Blue-Sky</u>.
 The Company shall use its commercially reasonable efforts to, if required by Applicable Law,
 (i) register and qualify the Common Shares covered by a Registration Statement under such
 other securities or "blue sky" laws of such jurisdictions in the United States
 as the Investor reasonably requests, (ii) prepare and file in those jurisdictions, such amendments
 (including post-effective amendments) and supplements to such registrations and qualifications
 as may be necessary to maintain the effectiveness thereof during the Commitment Period, (iii)
 take such other actions as may be necessary to maintain such registrations and qualifications
 in effect at all times during the Commitment Period, and (iv) take all other actions reasonably
 necessary or advisable to qualify the Common Shares for sale in such jurisdictions; provided,
 however, that the Company shall not be required in connection therewith or as a condition
 thereto to (w) make any change to its articles of incorporation or bylaws, (x) qualify to
 do business in any jurisdiction where it would not otherwise be required to qualify but for
 this Section 6.01(f), (y) subject itself to general taxation in any such jurisdiction, or
 (z) file a general consent to service of process in any such jurisdiction. The Company shall
 promptly notify the Investor of the receipt by the Company of any notification with respect
 to the suspension of the registration or qualification of any of the Common Shares for sale
 under the securities
 or "blue sky" laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threat
 of any proceeding for such purpose.

**Section 6.02 Suspension of Registration Statement**.

(a) <u>Establishment of a Black Out Period</u>. During the Commitment Period, the Company from time to time may suspend the use of the Registration Statement
by written notice to the Investor in the event that the Company determines in its sole discretion in good faith that such suspension
is necessary to (A) delay the disclosure of material nonpublic information concerning the Company, the disclosure of which at the time
is not, in the good faith opinion of the Company, in the best interests of the Company or (B) amend or supplement the Registration Statement
or prospectus so that such Registration Statement or prospectus shall not include an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading (a " <u>Black Out Period</u> ").

(b) <u>No Sales by Investor During the Black Out Period</u>. During such Black Out Period, the Investor agrees not to sell any Common Shares
 of the Company.

(c) <u>Limitations on the Black Out Period</u>. The Company shall not impose any Black Out Period that is longer than 60 days or in a manner that is
 more restrictive (including, without limitation, as to duration) than the comparable restrictions that the Company may impose on
 transfers of the Company's equity securities by its directors and senior executive officers. In addition, the Company shall
 not deliver any Advance Notice during any Black Out Period. If the public announcement of such material, nonpublic information is
 made during a Black Out Period, the Black Out Period shall terminate immediately after such announcement, and the Company shall
 immediately notify the Investor of the termination of the Black Out Period.

**Section 6.03 Listing of Common Shares.** As of each Advance Date, the Shares to be sold by the Company from time to time hereunder will have been registered under Section 12(b) of the Exchange Act and approved for listing on the Principal Market or Trading Market, subject to official notice of issuance.

**Section 6.04 Opinion of Counsel.** Prior to the date of the delivery by the Company of the first Advance Notice, the Investor shall have received an opinion and negative assurances letter from counsel to the Company in form and substance reasonably satisfactory to the Investor.

**Section 6.05 Exchange Act Registration.** The Company will use commercially reasonable efforts to file in a timely manner all reports and other documents required of it as a reporting company under the Exchange Act and will not take any action or file any document (whether or not permitted by Exchange Act or the rules thereunder) to terminate or suspend its reporting and filing obligations under the Exchange Act.

**Section 6.06 Transfer Agent Instructions.** For any time while there is a Registration Statement in effect for this transaction, the Company shall (if required by the transfer agent for the Common Shares) cause legal counsel for the Company to deliver to the transfer agent for the Common Shares (with a copy to the Investor) instructions to issue Common Shares to the Investor free of restrictive legends upon each Advance if the delivery of such instructions are consistent with Applicable Law and the Investor has provided the Transfer Agent Deliverables with respect to such Common Shares required by this Agreement.

**Section 6.07 Corporate Existence.** The Company will use commercially reasonable efforts to preserve and continue the corporate existence of the Company during the Commitment Period.

**Section 6.08 Notice of Certain Events Affecting Registration; Suspension of Right to Make an Advance.** The Company will promptly notify the Investor, and confirm in writing, upon its becoming aware of the occurrence of any of the following events in respect of a Registration Statement or related prospectus relating to an offering of Common Shares (in each of which cases the information provided to Investor will be kept strictly confidential): (i) except for requests made in connection with SEC or other Federal or state governmental authority investigations disclosed in the SEC Documents, receipt of any request for additional information by the SEC or any other Federal or state governmental authority during the period of effectiveness of the Registration Statement or any request for amendments or supplements to the Registration Statement or related prospectus; (ii) the issuance by the SEC or any other Federal governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Common Shares for sale in any jurisdiction or the initiation or written threat of any proceeding for such purpose; (iv) the happening of any event that makes any statement made in the Registration Statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related prospectus or documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or of the necessity to amend the Registration Statement or supplement a related prospectus to comply with the Securities Act or any other law; and (v) the Company's reasonable determination that a post-effective amendment to the Registration Statement would be appropriate; and the Company will promptly make available to the Investor any such supplement or amendment to the related prospectus. The Company shall not deliver to the Investor any Advance Notice, and the Company shall not sell any Shares pursuant any pending Advance Notice (other than as required pursuant to Section 2.05(d)), during the continuation of any of the foregoing events in clauses (i) through (v) above, or in the event that (vi) there shall be no bid for the Common Shares on the Principal Market or Trading Market for a period of 15 consecutive minutes at any time during the applicable Pricing Period or (vii) there shall be a "trading halt" or circuit breaker" event with respect to the Common Shares on the Principal Market or Trading Market during the applicable Pricing Period (each of the events described in the immediately preceding clauses (i) through (vii), inclusive, a "<u>Material Outside Event</u>").

**Section 6.09 Consolidation.** If an Advance Notice has been delivered to the Investor, then the Company shall not effect any consolidation of the Company with or into, or a transfer of all or substantially all the assets of the Company to another entity before the transaction contemplated in such Advance Notice has been closed in accordance with Section 2.05 hereof, and all Shares in connection with such Advance have been received by the Investor.

**Section 6.10 Issuance of the Company's Common Shares.** The issuance and sale of the Common Shares hereunder shall be made in accordance with the provisions and requirements of Section 4(a)(2) of the Securities Act or Regulation D under the Securities Act and any applicable state securities law.

**Section 6.11 Market Activities.** The Company will not, directly or indirectly, take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company under Regulation M of the Exchange Act.

**Section 6.12 Expenses.** The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay all expenses incident to the performance of its obligations hereunder, including but not limited to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, of each prospectus and of each amendment and supplement thereto; (ii) the preparation, issuance and delivery of any Shares issued pursuant to this Agreement, (iii) all reasonable fees and disbursements of the Company's counsel, accountants and other advisors, (iv) the qualification of the Shares under securities laws in accordance with the provisions of this Agreement, including filing fees in connection therewith, (v) the printing and delivery of copies of any prospectus and any amendments or supplements thereto, (vi) the fees and expenses incurred in connection with the listing or qualification of the Shares for trading on the Principal Market or Trading Market, or (vii) filing fees of the SEC and the Principal Market or Trading Market.

**Section 6.13 Current Report.** The Company shall not, and the Company shall cause each of its Subsidiaries and each of its and their respective officers, directors, employees and agents not to, provide the Investor with any material, non-public information regarding the Company or any of its Subsidiaries without the express prior written consent of the Investor (which may be granted or withheld in the Investor's sole discretion and must include an agreement to keep such information confidential until publicly disclosed or 45 days have passed); it being understood that the mere notification of Investor required pursuant to Section 6.08(iv) hereof shall not in and of itself be deemed to be material non-public information. Notwithstanding anything contained in this Agreement to the contrary, the Company expressly agrees that it shall use its commercial reasonable efforts to publicly disclose, no later than 45 days following the date hereof, but in any event prior to delivering the first Advance Notice hereunder, any information communicated to the Investor by or, to the knowledge of the Company, on behalf of the Company in connection with the transactions contemplated herein, which, following the date hereof would, if not so disclosed, constitute material, non-public information regarding the Company or its Subsidiaries.

**Section 6.14 Advance Notice Limitation.** The Company shall not deliver an Advance Notice if a shareholder meeting or corporate action date, or the record date for any shareholder meeting or any corporate action, would fall during the period beginning two Trading Days prior to the date of delivery of such Advance Notice and ending two Trading Days following the Closing of such Advance.

**Section 6.15 Use of Proceeds.** The Company will use the proceeds from the sale of the Common Shares hereunder for working capital and other general corporate purposes or, if different, in a manner consistent with the application thereof described in the Registration Statement. Neither the Company nor any Subsidiary will, directly or indirectly, use the proceeds of the transactions contemplated herein, or lend, contribute, facilitate or otherwise make available such proceeds to any Person (i) to fund, either directly or indirectly, any activities or business of or with any Person that is identified on the list of Specially Designated Nationals and Blocker Persons maintained by OFAC, or in any country or territory, that, at the time of such funding, is, or whose government is, the subject of Sanctions or Sanctions Programs, or (ii) in any other manner that will result in a violation of Sanctions.

**Section 6.16 Compliance with Laws.** The Company shall comply in all material respects with all Applicable Laws.

**Section 6.17 Aggregation**. From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its commercially reasonable efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under circumstances that would cause this offering of the Securities by the Company to the Investor to be aggregated with other offerings by the Company in a manner that would require shareholder approval pursuant to the rules of the Principal Market or Trading Market on which any of the securities of the Company are listed or designated, unless shareholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of such Principal Market or Trading Market.

**Section 6.18 Other Transactions**. The Company shall not enter into, announce or recommend to its shareholders any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Shares to the Investor in accordance with the terms of the Transaction Documents.

**Section 6.19 Integration**. From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its commercially reasonable efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under circumstances that would require registration of the offer and sale of any of the Securities under the Securities Act, without the prior written consent of the Investor.

**Section 6.20 Limitation on Variable Rate Transactions**. From the date hereof until the earlier of (i) the date that the Investor has purchased $50 million in Common Shares hereunder, (ii) 12 months after effectiveness of initial Registration Statement or (iii) three (3) months after any Termination hereunder (the "<u>Limitation Date</u>"), the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company of Common Shares or Common Share Equivalents (or a combination of units thereof) involving a Variable Rate Transaction, other than in connection with an Exempt Issuance or with the prior written consent of the Investor. The Investor shall be entitled to seek injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required.

"<u>Common Share Equivalents</u>" means any securities of the Company which entitle the holder thereof to acquire at any time Common Shares, including, without limitation, Common Shares, any debt, preferred shares, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.

"<u>Variable Rate Transaction</u>" means a transaction in which the Company (i) issues or sells any future equity or debt securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional Common Shares or Common Share Equivalents either (A) at a conversion price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Shares at any time after the initial issuance of such equity or debt securities (including, without limitation, pursuant to any "cashless exercise" provision), or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such equity or debt security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Shares (including, without limitation, any "full ratchet" or "weighted average" anti-dilution provisions, but not including any standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, share split, reverse share split or other similar transaction), (ii) issues or sells any equity or debt securities, including without limitation, Common Shares or Common Share Equivalents, either (A) at a price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Shares (other than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, share split, reverse share split or other similar transaction), or (B) that is subject to or contains any put, call, redemption, buy-back, price-reset or other similar provision or mechanism (including, without limitation, a "Black-Scholes" put or call right) that provides for the issuance of additional equity securities of the Company or the payment of cash by the Company, or (iii) enters into any agreement, including, but not limited to, an at-the-market offering or "equity line" (that is not an Exempt Issuance) or other continuous offering or similar offering of Common Shares or Common Share Equivalents, whereby the Company may sell Common Shares or Common Share Equivalents at a future determined price.

"<u>Exempt Issuance</u>" means the issuance of (a) Common Shares, options, restricted stock units or other equity incentive awards to employees, officers, consultants, directors or vendors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by the Board of Directors of the Company or a majority of the members of a committee of directors established for such purpose, (b) any Shares issued to the Investor pursuant to this Agreement, (c) Common Shares, Common Share Equivalents or other securities issued to the Investor pursuant to any other existing or future contract, agreement or arrangement between the Company and the Investor, (d) Common Shares, Common Share Equivalents or other securities upon the exercise, exchange or conversion of any Common Shares, Common Share Equivalents or other securities held by the Investor at any time, (e) any securities issued upon the exercise or exchange of or conversion of any Common Share Equivalents issued and outstanding on the date hereof, provided that such securities or Common Share Equivalents referred to in this clause (e) have not been amended since the date hereof to increase the number of such securities or Common Shares underlying such securities or to decrease the exercise price, exchange price or conversion price of such securities, (f) Common Share Equivalents that are convertible into, exchangeable or exercisable for, or include the right to receive Common Shares at a conversion price, exercise price, exchange rate or other price (which may be below the then current market price of the Common Shares) that is fixed at the time of initial issuance of such Common Share Equivalents (subject only to standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, share split, reverse share split or other similar transaction), which fixed conversion price, exercise price, exchange rate or other price shall not at any time after the initial issuance of such Common Share Equivalent be based upon or varying with the trading prices of or quotations for the Common Shares or subject to being reset at some future date and (g) securities issued pursuant to acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions approved by the Board of Directors of the Company or a majority of the members of a committee of directors established for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions can have a Variable Rate Transaction component, provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. In the event that the Company enters into a Variable Rate Transaction in breach of this section, the Company shall promptly pay to Investor $250,000 in cash.

**Section 6.21 DTC**. The Company shall take all action reasonably required to ensure that its Common Shares can be transferred electronically as DWAC Shares if the Transfer Agent Deliverables with respect to such Common Shares have been provided by the Investor.

**Section 6.22 Non-Public Information**. Each party hereto agrees not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby in full compliance with applicable securities laws; provided, however that a party may disclose Confidential Information that is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes material, non-public information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD under the Exchange Act. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information that constitutes material, non-public information, the Company shall have at least twenty-four (24) hours to publicly disclose such material, non-public information prior to any such disclosure by the Investor, and the Company shall have failed to publicly disclose such material, non-public information within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, shareholders or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company.

**Section 6.23 Prohibition of Short Sales and Hedging Transactions.** The Investor agrees that beginning on the date of this Agreement and ending on the date of termination of this Agreement as provided in Section 11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) "short sale" (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Shares (excluding transactions properly marked "short exempt") or (ii) hedging transaction, which establishes a net short position with respect to the Common Shares.

**Section 6.24 Use of Name.** The Company shall not, directly or indirectly, use the names "Arena Business Solutions Global", "Arena Business Results", "Arena Management Company, LLC", "Arena Finance Company, LLC", or "Arena", or any derivations thereof, or logos associated with these names, as the case may be, in any manner or take any action that may imply any relationship with the Investor or any of its Affiliates without the prior written consent of the Investor, provided, however, the Investor hereby consents to all lawful uses of these names in the prospectus, statement and other materials that are required by applicable laws or pursuant to the disclosure requirements of the SEC or any state securities authority.

**ARTICLE VII**

**CONDITIONS FOR DELIVERY OF ADVANCE NOTICE**

**Section 7.01 Conditions Precedent to the Right of the Company to Deliver an Advance Notice.** The right of the Company to deliver an Advance Notice and the obligations of the Investor hereunder with respect to an Advance is subject to:

(a) the
 satisfaction by the Company, on each Advance Notice Date (a " <u>Condition Satisfaction Date</u> "), of each of the following conditions:

(b) <u>Accuracy of the Company's Representations and Warranties</u>. The representations and warranties
 of the Company in this Agreement shall be true and correct in all material respects.

(c) <u>Registration of the Common Shares with the SEC</u>. There is an effective Registration Statement pursuant
 to which the Investor is permitted to utilize the prospectus thereunder to resell all of
 the Registrable Securities. The Company shall have filed with the SEC all reports, notices
 and other documents required under the Exchange Act and applicable SEC regulations during
 the twelve-month period immediately preceding the applicable Condition Satisfaction Date.

(d) <u>Authority</u>.
 The Company shall have obtained all permits and qualifications required by any applicable
 state for the offer and sale of all the Common Shares issuable pursuant to such Advance Notice,
 or shall have the availability of exemptions therefrom. The sale and issuance of such Common
 Shares shall be legally permitted by all laws and regulations to which the Company is subject.

(e) <u>No Material Outside Event or Material Adverse Effect</u>. No Material Outside Event or Material
 Adverse Effect shall have occurred and be continuing.

(f) <u>Performance by the Company</u>. The Company shall have performed, satisfied and complied in all material
 respects with all covenants, agreements and conditions required by this Agreement to be performed,
 satisfied or complied with by the Company at or prior the applicable Condition Satisfaction
 Date including, without limitation, the delivery of all Common Shares issuable pursuant to
 all previously delivered Advance Notices and the issuance of all Commitment Fee Shares previously
 required to be issued to Investor (for the avoidance of doubt, if the Company shall have
 performed, satisfied and complied in all material respects with all covenants, agreements
 and conditions required by this Agreement at the time of the applicable Condition Satisfaction
 Date, but did not comply with any timing requirement set forth herein, then this condition
 shall be deemed satisfied unless the Investor is materially prejudiced by the failure of
 the Company to comply with any such timing requirement) and the issuance of the Commitment
 Fee Shares free of any restrictive legends in accordance with Section 13.04 herein.

(g) <u>No Injunction</u>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly, materially and adversely affects
any of the transactions contemplated by this Agreement.

(h) <u>No Suspension of Trading in or Delisting of Common Shares</u>. The Common Shares are quoted for trading on the Principal Market or Trading
Market and all of the Shares issuable pursuant to such Advance Notice will be listed or quoted for trading on the Principal Market or
Trading Market. The Company shall not have received any written notice that is then still pending threatening the continued quotation
of the Common Shares on the Principal Market or Trading Market.

(i) <u>Authorized</u>.
 There shall be a sufficient number of authorized but unissued and otherwise unreserved Common
 Shares for the issuance of all of the Shares issuable pursuant to such Advance Notice.

(j) <u>Executed Advance Notice</u>. The representations contained in the applicable Advance Notice shall
 be true and correct in all
 material respects as of the applicable Condition Satisfaction Date.

(k) <u>Consecutive Advance Notices</u>. Except with respect to the first Advance Notice, the Pricing Period
 for all prior Advances has been completed.

(l) <u>Shareholder Approval</u>. The Company shall have (i) issued and registered all of the Commitment Fee Shares and (ii) obtained Shareholder Approval
 to issue Common Shares in excess of the Exchange Cap hereunder.

Furthermore, the Company shall not have the right to deliver an Advance Notice to the Investor if any of the following shall occur:

(m) [Intentionally
 omitted]

(n) the
 Company breaches any representation or warranty in any material respect, or breaches any
 covenant or other term or condition under any Transaction Document in any material respect,
 and except in the case of a
 breach of a covenant which is reasonably curable, only if such breach continues for a period
 of at least five (5) consecutive Business Days;

(o) if
 any Person commences a proceeding against the Company pursuant to or within the meaning of
 any Bankruptcy Law for so
 long as such proceeding is not dismissed;

(p) if
 the Company is at any time insolvent, or, pursuant to or within the meaning of any Bankruptcy
 Law, (i) commences a voluntary case, (ii) consents to the entry of an order for relief against
 it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for
 all or substantially all of its property, or (iv) makes a general assignment for the benefit
 of its creditors or (v) the Company is generally unable to pay its debts as the same become
 due;

(q) a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company in an involuntary
case, (ii) appoints a Custodian of the Company or for all or substantially all of its property, or (iii) orders the liquidation of the
Company or any Subsidiary for so long as such order, decree or similar action remains in effect; or

(r) if
 at any time the Company is not eligible or is unable to transfer its Shares to Investor,
 including, without limitation, electronically through DTC's Deposit/Withdrawal At Custodian
 system.

**ARTICLE VIII**

**NON-DISCLOSURE OF NON-PUBLIC INFORMATION**

The Company covenants and agrees that, other than as expressly required by Section 6.08 hereof or, with the Investor's consent pursuant to Section 6.01(c) and 6.13, it shall refrain from disclosing, and shall cause its officers, directors, employees and agents to refrain from disclosing, any material non-public information (as determined under the Securities Act, the Exchange Act, or the rules and regulations of the SEC) directly or indirectly to the Investor or its affiliates, without also disseminating such information to the public, unless prior to disclosure of such information the Company identifies such information as being material non-public information and provides the Investor with the opportunity to accept or refuse to accept such material non-public information for review. Unless specifically agreed to in writing, in no event shall the Investor have a duty of confidentiality, or be deemed to have agreed to maintain information in confidence, with respect to the delivery of any Advance Notices.

**ARTICLE IX**

**NON EXCLUSIVE AGREEMENT**

Notwithstanding anything contained herein, this Agreement and the rights awarded to the Investor hereunder are non-exclusive, and the Company may, at any time throughout the term of this Agreement and thereafter, issue and allot, or undertake to issue and allot, any shares and/or securities and/or convertible notes, bonds, debentures, options to acquire shares or other securities and/or other facilities which may be converted into or replaced by Common Shares or other securities of the Company, and to extend, renew and/or recycle any bonds and/or debentures, and/or grant any rights with respect to its existing and/or future share capital.

**ARTICLE X**

**CHOICE OF LAW/JURISDICTION**

This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The parties further agree that any action between them shall be heard in New York County, New York, and expressly consent to the jurisdiction and venue of the Supreme Court of New York, sitting in New York County, New York and the United States District Court of the Southern District of New York, sitting in New York, New York, for the adjudication of any civil action asserted pursuant to this Agreement.

**ARTICLE XI**

**ASSIGNMENT; TERMINATION**

**Section 11.01 Assignment.** Neither this Agreement nor any rights or obligations of the parties hereto may be assigned to any other Person.

**Section 11.02 Termination**.

(a) Unless
 earlier terminated as provided hereunder, this Agreement shall terminate automatically on the earliest of (i) the first day of the
 month next following the 36-month anniversary of the date hereof or (ii) the date on which the Investor shall have made payment of
 Advances pursuant to this Agreement for Common Shares equal to the Commitment Amount.

(b) The
 Company may terminate this Agreement effective upon five Trading Days' prior written notice to the Investor; provided that (i)
 there are no outstanding Advance Notices, the Common Shares under which have yet to be issued, and (ii) the Company has paid all
 amounts owed to the Investor pursuant to this Agreement including, without limitation, all Commitment Fee Shares. This Agreement may
 be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written consent
 unless otherwise provided in such written consent.

(c) Nothing
 in this Section 11.02 shall be deemed to release the Company or the Investor from any liability for any breach under this Agreement,
 or to impair the rights of the Company and the Investor to compel specific performance by the other party of its obligations under
 this Agreement. The indemnification provisions contained in Article V shall survive termination hereunder.

**ARTICLE XII**

**NOTICES**

Other than with respect to Advance Notices, which must be in writing and will be deemed delivered on the day set forth in Section 2.02 in accordance with <u>Exhibit C</u>, any notices, consents, waivers, or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile or e-mail if sent on a Trading Day, or, if not sent on a Trading Day, on the immediately following Trading Day; (iii) 5 days after being sent by U.S. certified mail, return receipt requested, (iv) 1 day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications (except for Advance Notices which shall be delivered in accordance with <u>Exhibit A</u> hereof) shall be:

---

| | |
|:---|:---|
| If to the Company, to: | ASPIRE BIOPHARMA HOLDINGS, INC.<br> 23150 Fashion Drive, Suite 232<br> Estero, Florida 33928<br> Attn: Earnest Scheidemann<br> Email: escheidemann@aspire-biopharma.com |
| With a Copy (which shall not constitute notice or delivery of process) to: | Stephen Quesenberry, Esq.<br> PO Box 12<br> Salem, UT 84653<br> Email: steve@kittsgroup.com |
| If to the Investor(s): | ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD<br> 405 Lexington Ave, 59th Floor New York, NY 10174 Attention: Yoav Stramer Telephone: (212) 752-2568 Email: <u>ystramer@arenaco.com</u> |
| With a Copy (which shall not constitute notice or delivery of process) to: | Pryor Cashman LLP 7 Times Square<br> New York, New York 10036 Attention: Matthew Ogurick, Esq. Telephone: (212) 326-0243<br> Email: mogurick@pryorcashman.com |

---

Either may change its information contained in this Article XII by delivering notice to the other party as set forth herein.

**ARTICLE XIII**

**MISCELLANEOUS**

**Section 13.01 Counterparts.** This Agreement may be executed in identical counterparts, both which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Facsimile or other electronically scanned and delivered signatures, including by e-mail attachment, shall be deemed originals for all purposes of this Agreement.

**Section 13.02 Entire Agreement; Amendments.** This Agreement supersedes all other prior oral or written agreements between the Investor, the Company, their respective affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement contains the entire understanding of the parties with respect to the matters covered herein and, except as specifically set forth herein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the parties to this Agreement. The provisions of the existing confidentiality agreement between the Investor and the Company shall remain in force, except that all provisions therein dealing with the treatment of material non-public information are superseded by this Agreement.

**Section 13.03 Reporting Entity for the Common Shares.** The reporting entity relied upon for the determination of the trading price or trading volume of the Common Shares on any given Trading Day for the purposes of this Agreement shall be Bloomberg, L.P. or any successor thereto. The written mutual consent of the Investor and the Company shall be required to employ any other reporting entity.

**Section 13.04 Due Diligence Fee; Commitment Fee Shares.**

(a) Each
 of the parties shall pay its own fees and expenses (including the fees of any attorneys,
 accountants, appraisers or others engaged by such party) in connection with this Agreement
 and the transactions contemplated hereby, except that the Company shall be responsible for
 all of Investor's customary due diligence
 and legal fees (and will provide proof of any retainer payments and engagement letters),
 including, without limitation, $40,000 incurred in prior transaction by and between the parties
 (of which $15,000 was previously paid) and approximately $20,000 for this current transaction,
 with $20,000 to be paid in cash upon execution and delivery of this Agreement and the remainder
 of the balance owed being paid in Common Shares (the " <u>Transaction Fee Shares</u> ")
 based on a price equal to the lowest 1-Trading Day VWAP of the Common Shares of the five
 (5) Trading Days immediately preceding the date of execution and delivery of this Agreement.
 The Transaction Fee Shares shall be subject to the same true-up provisions as the Commitment
 Fee Shares as described in this Agreement and shall also be registered for resale in same
 manner as the Commitment Fee Shares are to be registered for resale pursuant to the terms
 of this Agreement.

---

| | |
|:---|:---|
| (b) | In consideration for the Investor's execution and delivery of this Agreement, the Company shall issue or cause to be issued or transferred to the Investor that number of additional Common Shares equal to 250,000 divided by the lowest 1-Trading Day VWAP of the Common Shares of the five (5) Trading Days immediately preceding the effectiveness of the initial registration statement (the "<u>Initial Registration Statement</u>") on which Commitment Fee Shares are to be registered (the "<u>Price</u>"), promptly (but in no event later than one (1) Trading Day) after the effectiveness of the Registration Statement (the "<u>Share Issuance</u>"). |
|  | The price calculation set forth above will capture up to the date before such registration statement becomes effective. For any time while there is a Registration Statement in effect for this transaction, the Company shall (if required by the transfer agent) deliver to the transfer agent for the Common Shares (with a copy to the Investor) instructions to issue the Commitment Fee Shares to the Investor free of restrictive legends, in each case supported as needed by an opinion from legal counsel for the Company. All of the Commitment Fee Shares shall be deemed fully earned as of the date hereof. For the avoidance of any doubt, in the event that this Agreement is terminated prior to the Share Issuance for any reason, the Company shall nevertheless be obligated to effect the remaining issuance of Commitment Fee Shares hereunder immediately upon such termination based on the per Common Share price which price shall be equal to the lowest 1-Trading Day VWAP of the Common Shares of the five (5) Trading Days immediately preceding the date of such Termination. |
| (c) | The Commitment Fee Shares shall be subject to a true-up after issuance pursuant to subsection (b) above whereby the Company shall deliver irrevocable instructions to its transfer agent to electronically transfer to the Investor or its designee(s) that number of Common Shares having an aggregate dollar value equal to 250,000 based on the lower of (A) the Price and (B) the lower of (a) the simple average of the three (3) lowest daily intraday trade prices over the twenty (20) Trading Days after (and not including) the date of effectiveness of the Initial Registration Statement and (b) the closing price on the twentieth (20th) Trading Day after the effectiveness of the Initial Registration Statement. |
| (d) | The Company shall therefore promptly (but in no event later than one (1) Trading Day) issue to the Company the Commitment Fee Shares based on the pricing formulae hereinabove at the Price upon effectiveness of the Registration Statement , and shall, if applicable, issue additional Commitment Fee Shares to the Investor promptly (but in no event later than one (1) Trading Day after the end of the pricing period described in the preceding clause (d) to the extent such additional Commitment Fee Shares are issuable pursuant to the terms of this Section 13.04.. |

---

**Section 13.05 Brokerage.** Each of the parties hereto represents that it has had no dealings in connection with this transaction with any finder or broker who will demand payment of any fee or commission from the other party. The Company on the one hand, and the Investor, on the other hand, agree to indemnify the other against and hold the other harmless from any and all liabilities to any person claiming brokerage commissions or finder's fees on account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby.

***[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]***

 ****

**IN WITNESS WHEREOF**, the parties hereto have caused this Purchase Agreement to be executed by the undersigned, thereunto duly authorized, as of the date first set forth above.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| **ASPIRE BIOPHARMA HOLDINGS, INC.** | **ASPIRE BIOPHARMA HOLDINGS, INC.** |
| By: |  |
| Name: | Kraig Higginson |
| Title: | CEO |
| **INVESTOR:** | **INVESTOR:** |
| **ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD** | **ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD** |
| By: |  |
| Name: |  |
| Title: |  |

---

**IN WITNESS WHEREOF**, the parties hereto have caused this Purchase Agreement to be executed by the undersigned, thereunto duly authorized, as of the date first set forth above.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| **ASPIRE BIOPHARMA HOLDINGS, INC.** | **ASPIRE BIOPHARMA HOLDINGS, INC.** |
| By: |  |
| Name: | Kraig Higginson |
| Title: | Chief Executive Officer |
| **INVESTOR:** | **INVESTOR:** |
| **ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD** | **ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD** |
| By: |  |
| Name: | Lawrence Cutler |
| Title: | Authorized Signatory |

---

**EXHIBIT A**

**ADVANCE NOTICE**

ASPIRE BIOPHARMA HOLDINGS, INC.

Dated: ___________Advance Notice Number: _______

The undersigned, ______________________, hereby certifies, with respect to the sale of Common Shares of ASPIRE BIOPHARMA HOLDINGS, INC. (the "<u>Company</u>") issuable in connection with this Advance Notice, delivered pursuant to that certain Purchase Agreement, dated as of October __, 2025 (the "<u>Agreement</u>"), as follows:

1 The undersigned is the duly elected _______________of the Company.

---

| | |
|:---|:---|
| 2 | There are no fundamental changes to the information set forth in the Registration Statement which would require the Company to file a post-effective amendment to the Registration Statement. |

---

3 All conditions to the delivery of this Advance Notice are satisfied as of the date hereof.

4 The number of Common Shares that the Company is requesting in this Advance is _____________________.

5 The number of Common Shares of the Company issued and outstanding as of the date hereof is ___________.

6 The Pricing Period shall be one (1) Trading Day.

The undersigned has executed this Advance Notice as of the date first set forth above.

---

| |
|:---|
| **ASPIRE BIOPHARMA HOLDINGS, INC.** |
| By: |
| Name: |
| Title: |

---

**EXHIBIT B**

**FORM OF SETTLEMENT DOCUMENT**

**VIA EMAIL**

ASPIRE BIOPHARMA HOLDINGS, INC.

Attn:

Email:

Subject:

Below please find the settlement information with respect to the Advance Notice Date of:

1. Amount
 of Advance requested in the Advance Notice

2. Adjusted
 Advance (after taking into account any adjustments pursuant to Section 2.01):

3. Market
 Price

4. Purchase
 Price (Market Price x 96.0%) per share

5. Number
 of Shares due to Investor

**Please issue the number of Shares due to the Investor to the account of the Investor as follows:**

**INVESTOR'S DTC PARTICIPANT #<sup>1</sup>:**

ACCOUNT NAME: ACCOUNT NUMBER: ADDRESS:

CITY:

COUNTRY:

CONTACT PERSON:

NUMBER AND/OR EMAIL:

---

| |
|:---|
| **Sincerely,** |
| **ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD** |
| By: |
| Name: |
| Title: |

---

<sup>1</sup> Investor understands and acknowledges that shares will be issued in book-entry form on the DRS of the transfer agent or certificated unless the conditions set forth in Section 2.05(b) have been satisfied

---

| |
|:---|
| **Agreed and Approved:** |
| **ASPIRE BIOPHARMA HOLDINGS, INC.** |
| By: |
| Name: |
| Title: |

---

**SCHEDULE 1**

**Authorized Representatives**

The following individuals may execute Advance Notices:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Ernest Scheidemann

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Kraig Higginson

**EXHIBIT C**

**VIA EMAIL**

Email: ELOC@arenaco.com

Subject: ELOC: ASPIRE BIOPHARMA HOLDINGS, INC.

Advance Notice

Below please find the Advance Notice Date of:

1. Amount
 of Advance Shares:

2. Time
 of Advance: